Verdemed
Verdemed is a Canadian-incorporated pharmaceutical company founded in 2018 that develops, distributes, and licenses medical cannabis products targeting Latin American markets, with operational footholds in Brazil and Colombia.
- Company typePrivate
- Founded2018
- HeadquartersToronto, Canada
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Verdemed does
Verdemed is a Canadian-incorporated pharmaceutical company, founded in 2018 and headquartered in Toronto, that develops and distributes medical cannabis products targeted at Latin American markets. The company's commercial focus spans seven countries — Argentina, Brazil, Chile, Colombia, Mexico, Peru, and Uruguay — representing a combined population of approximately 579 million, with operational footholds established in Brazil (via the Mydstein Laboratory acquisition) and Colombia (via a stake in licensed producer Greenfarma in Cali).
The product portfolio includes CBD gel capsules in 5mg, 10mg, and 20mg strengths with filed/pending patent protection on the proprietary formulation; a CBD oral solution modeled on Epidiolex for refractory epilepsy; THC/CBD gel capsules in clinical evaluation for insomnia; a THC/CBD oral spray modeled on Sativex for multiple sclerosis; and THC gel capsules modeled on dronabinol. Alongside the product business, Verdemed operates the Verdemed Care platform — an information and service portal that connects patients with physicians and supports medical cannabis import workflows across Brazil, Colombia, and Mexico. Colombian production capacity is anchored by Greenfarma at approximately 1,000 liters of cannabis oil per year.
The business model combines pharmaceutical product sales, platform services through Verdemed Care, and strategic partnership/licensing arrangements, executed via a sales-led, event-driven go-to-market targeting LATAM healthcare providers and patients. Verdemed has built explicit regulatory capabilities across six national agencies — ANMAT, ANVISA, COFEPRIS, DIGEMID, INVIMA, and ISP — supported by a leadership team with prior experience at Canopy Growth's Latam operations, ACIC Pharmaceuticals, and major pharma firms including GE, GSK, Pfizer, and AstraZeneca. As of the latest available data (mid-to-late 2019), the company had raised approximately $12.7M cumulatively and was pursuing a $9M Series B to fund a stated $80M Brazil investment plan through 2022.
Verdemed firmographics
Firmographics- Name
- Verdemed
- Legal name
- Verdemed Holdings Inc.
- Website
- https://verdemed.com
- Company type
- Private
- Founded year
- 2018
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Verdemed is a Canadian-incorporated pharmaceutical company founded in 2018 that develops, distributes, and licenses medical cannabis products targeting Latin American markets, with operational footholds in Brazil and Colombia.
- Ownership category
- akta.pro rank
Verdemed industry classification
Industry- NAICS
- Medicinal and Botanical Manufacturing (325411), Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254), Pharmaceutical and Medicine Manufacturing (32541)
- SIC
- Medicinal Chemicals & Botanical Products (2833), Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Cannabis Dispensary + Pharmacy/Clinical Model (Patient Services) (CRANAFAI)
Keywords
Where Verdemed is headquartered
LocationHeadquarters
- HQ city
- Toronto
- HQ country
- Canada
- HQ region
- North America
Offices3 records
Markets served
Verdemed business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales, Infrastructure
Revenue model
- Pharmaceutical Product Sales: Verdemed generates revenue through the sale of pharmaceutical-grade cannabinoid-based medications including CBD and THC products, capsules, and oral solutions. Products are distributed through pharmacies in Brazil and via the Verdemed Care e-commerce platform for direct patient importation support.
- Verdemed Care Platform Services: The company operates a platform providing information, physician connections, and importation support services for patients seeking cannabis-based treatments in Latin America.
- Strategic Partnerships and Licensing: Verdemed positions itself as the platform of choice for global pharmaceutical innovators entering the Latin American cannabis market, potentially through licensing agreements, co-development partnerships, and regulatory navigation services.
Go-to-market motion2 records
Distribution channels3 records
Marketing channels3 records
Verdemed product offering
Product offeringCore offering
Verdemed develops, manufactures, and distributes pharmaceutical-grade cannabinoid-based medications including CBD gel capsules (5/10/20 mg), CBD oral solution, THC/CBD gel capsules, THC/CBD oral spray, and THC gel capsules targeting epilepsy, chronic pain, multiple sclerosis spasticity, insomnia, and chemotherapy-induced nausea. The company sells through licensed pharmacies in Brazil via its ANVISA-authorized Mydstein laboratory, the Verdemed Care patient/physician support platform, and licensed production in Colombia, while also acting as a LATAM regulatory and distribution partner for global pharmaceutical companies with cannabis products.
Product overview
Verdemed is a Canadian pharmaceutical company operating in Latin America that offers a portfolio of cannabis-based medications. The core product is the Verdemed Care platform, which provides information, physician connections, and import support services. The pharmaceutical product line includes CBD gel capsules (5/10/20mg with patented formula), CBD oral solution (similar to Epidiolex), THC/CBD gel capsules for insomnia clinical trials, THC/CBD oral spray (similar to Sativex/nabiximols), and THC gel capsules (similar to dronabinol). The company acquired Mydstein Laboratory in São Paulo to facilitate product distribution in Brazil.
Differentiator
Problem solved
Functional benefit
Brands
- Verdemed Care: An information portal and support platform for importing cannabinoid-based products, providing data on medical marijuana use, technical content for physicians, and guidance on direct import procedures.
Quantifiable outcome
- 20% market share target in Brazil's medical cannabis market by 2020
- +2 more outcomes
Companies that use Verdemed
Customer profileNamed customers2 records
Segments4 records
Ideal customer profiles4 records
Verdemed technology and API
TechnologyAPI detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
Verdemed partnerships and signals
Strategic signalPartnerships
Eight partnerships are on record, tiered core and minor.
- BenzingacoreVerdemed sponsored the Benzinga Cannabis Capital Conference in Chicago (October 2019), one of the largest cannabis investment conferences in North America. Verdemed previously participated in Benzinga events in Toronto (January 2019) and Miami (January 2019), using these platforms to connect with investors and develop business relationships in the cannabis sector.
- Lide FuturocoreVerdemed sponsored the second Like the Future Cannabusiness forum organized by Lide Futuro in São Paulo, Brazil (October 2019). Verdemed participated in multiple Lide Futuro events focused on medical cannabis regulation and business opportunities, engaging with regulators, industry leaders, and potential investors in the Brazilian market.
- Wayland GroupminorWayland Group, a Canadian cannabis company valued at USD 54 million, engaged in acquisition discussions with Verdemed in early 2019. Wayland proposed acquiring 10% of Verdemed for USD 6 million to create a global cannabis enterprise, with the goal of combining Wayland's existing operations with Verdemed's Latin American market position. The negotiations were described as serious but preliminary, with potential completion before Carnival 2019. The deal did not proceed as described publicly.
- Brainlike Regulatory StrategycoreBrainlike Regulatory Strategy provides specialized regulatory affairs consulting for Latin America, developing and managing product-specific regulatory strategies based on patented data, facilitating registrations with health authorities. Brainlike supports Verdemed in obtaining and maintaining marketing authorizations, legalizing companies, certifying good practices, training teams, technical translations, risk analysis, promotional material approval, and strategic portfolio reviews across LATAM regulatory bodies.
- CannX BrasilminorVerdemed sponsored the first CannX Brasil - International Congress on Cannabinoid Medicine (November 2018, São Paulo). The congress focused on research and clinical experience in medical cannabis, aligning with Verdemed's core operational priorities of clinical studies and medical expertise.
- Kahner GlobalcoreVerdemed sponsored and spoke at the Cannabis Private Investment Summit organized by Kahner Global, held in Toronto (October 2018) and Fort Lauderdale, Florida (February 2019). These events connect cannabis entrepreneurs with high-net-worth investors and family offices, providing Verdemed with access to capital markets and investment community relationships.
- LiveWellminorVerdemed participated in LiveWell's CBD Hemp Investor Series across Canada in September 2018, as part of efforts to educate investors about industrial hemp-derived CBD and connect with the broader North American cannabis investment community.
- Greenfarma (Cali, Colombia)coreVerdemed acquired a significant stake in Greenfarma, a Colombian licensed cannabis producer based in Cali. Greenfarma operates a 3,000 sq ft indoor growing and industrial extraction facility, fully licensed to plant, grow, extract, formulate, and sell medicinal cannabis products. The partnership provides Verdemed with local production capabilities in Latin America, producing approximately 1,000 liters of cannabis oil annually.
Scale indicators7 records
Recent moves6 records
Expansion highlights7 records
Verdemed competitors and assessment
Company assessmentDirect peers
- Khiron Life Sciences: Canadian-listed cannabis company with a primary strategic focus on medical cannabis in Latin America (Colombia, Mexico, Brazil, Peru). Directly comparable to Verdemed in target market and pharmaceutical positioning.
- PharmaCielo: Canadian parent of a Colombian licensed cannabis producer (Rionegro) supplying CBD/THC extracts to LATAM and international markets. Directly comparable to Verdemed on the Colombian cultivation and extraction side.
- Clever Leaves: Colombian-licensed cannabis cultivator and manufacturer with EU GMP certification exporting to LATAM, Europe, and beyond. Comparable on Colombian production, pharmaceutical-grade positioning, and cross-border distribution.
Broad incumbents
- Canopy Growth Corporation: Canadian cannabis incumbent that previously operated Canopy Latam and employed several of Verdemed's senior leaders. A broad LATAM-focused incumbent offering overlapping product/market ambitions with substantially greater capital.
- GW Pharmaceuticals (Jazz Pharmaceuticals): Developer of Sativex (nabiximols) and Epidiolex — the exact products Verdemed's portfolio is benchmarked against. Sets the clinical and regulatory benchmark for cannabis-derived pharmaceuticals globally and in any LATAM launch.
- Tilray Brands: Large Canadian licensed producer with established international operations and medical cannabis distribution across LATAM and Europe. Comparable as a broad incumbent pursuing medical cannabis export into Latin America.
- Aurora Cannabis: Canadian licensed producer with international medical cannabis distribution. Comparable as a broad incumbent with multi-country regulatory expertise and pharmacy channel access relevant to LATAM.
- Cronos Group: Canadian licensed producer with global ambitions (including a strategic investment from Altria). Comparable as a broad incumbent whose international expansion path could overlap with Verdemed's gateway-to-LATAM model.
Emerging players
- MediPharm Labs: Canadian cannabis company focused on pharmaceutical-grade cannabis concentrates and GMP-certified manufacturing. Comparable to Verdemed on the pharmaceutical-manufacturing angle and on serving as a white-label/API supplier.
- Entourage Health (formerly WeedMD): Canadian producer with pharmaceutical-grade capabilities and clinical focus. Comparable as a smaller, pharmaceutical-oriented Canadian cannabis operator seeking international growth.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat4 records
Key risks5 records
Key highlights5 records
Customer concentration
Verdemed social profiles
Digital presenceVerdemed financial estimates
Financial estimateRevenue estimate
Valuation estimate
Verdemed leadership team
Management profileNumber of profiles
Verdemed subsidiaries and ownership
Company hierarchySubsidiaries2 records
Verdemed funding detail
Funding detailFunding overview
Funding rounds4 records
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Verdemed M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Verdemed
What does Verdemed do?
Verdemed develops, manufactures, and distributes pharmaceutical-grade cannabinoid-based medications including CBD gel capsules (5/10/20 mg), CBD oral solution, THC/CBD gel capsules, THC/CBD oral spray, and THC gel capsules targeting epilepsy, chronic pain, multiple sclerosis spasticity, insomnia, and chemotherapy-induced nausea. The company sells through licensed pharmacies in Brazil via its ANVISA-authorized Mydstein laboratory, the Verdemed Care patient/physician support platform, and licensed production in Colombia, while also acting as a LATAM regulatory and distribution partner for global pharmaceutical companies with cannabis products.
Is Verdemed a public or private company?
Verdemed is a private company. It is currently operating.
When was Verdemed founded?
Verdemed was founded in 2018. It employs 11 to 50 people.
Where is Verdemed based?
Verdemed is headquartered in Toronto, Canada, in the North America region.
How does Verdemed make money?
Three revenue lines are on record. Pharmaceutical Product Sales are the primary driver. The others are verdemed Care Platform Services and strategic Partnerships and Licensing.
Who are Verdemed's main competitors?
Direct peers on record are Khiron Life Sciences, PharmaCielo and Clever Leaves. Broad incumbents are Canopy Growth Corporation, GW Pharmaceuticals (Jazz Pharmaceuticals), Tilray Brands, Aurora Cannabis and Cronos Group. Emerging players are MediPharm Labs and Entourage Health (formerly WeedMD).
Does Verdemed have an API?
No public API is recorded for Verdemed.
What industry is Verdemed in?
Its primary akta.pro industry code is CRANAFAI, Cannabis Dispensary + Pharmacy/Clinical Model (Patient Services). Its NAICS code is 325411 and its SIC code is 2833.